Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression. - Wikidata - wikimedia - TriplyDB

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

http://www.wikidata.org/entity/Q35770478

about

CITED1 expression in Wilms' tumor and embryonic kidney Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity Race disparities in Wilms tumor incidence and biology.Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers The E2F3-Oncomir-1 axis is activated in Wilms' tumor.TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy.Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.Heterochromatin protein 1 expression is reduced in human thyroid malignancy.Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.

P2860

Q24337902-A7854399-8B85-44AE-9B6A-223CC7BAE51D Q28571256-6FC8D9CE-69C8-455F-A0F0-875000B8331F Q30464239-30A3C15B-87A7-4CFE-A1F4-DFBD17A71568 Q34761951-6D7B4FF0-2BE8-42CC-B25D-0F0BCB49137A Q35151124-B07E2E30-CD19-41F5-97C8-0C27B018F238 Q36742470-51A2BB89-0ED2-40D1-B583-CC1C386BBFA2 Q37188707-7DA6298C-D1F0-4231-8D71-A16EE32E05EC Q37210764-837AE9A7-74AD-496D-9C67-36DC5462BA0A Q38421115-67DE6314-5FFD-4615-9983-F9D291A51E29 Q38611497-A34BD96B-F23B-40DF-B0BA-5CA68973E8C0 Q38993801-24199CE1-02A3-4643-A69A-F335EBFD2E3C Q39897131-877653E1-19BA-4127-8644-27B0607C9B3A Q40772764-3A27E167-E051-4859-BC6F-8D11E1832841 Q54540314-6F5019B8-6512-4EBF-8206-195472C43755

P2860

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

http://www.wikidata.org/entity/Q35770478

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@ast

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@en

type

label

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@ast

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@en

prefLabel

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@ast

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.

@en

P1433

Q35770478-5A608E1B-6525-43FE-9BF1-D472A5D75487

P1476

Q35770478-02518E63-E818-4BB1-AFF6-4DDE02010734

P2093

Q35770478-0CFF973B-E38B-4596-A9CB-21D304000CA1

Q35770478-11512174-B085-4A44-A5FC-D5B64E059B90

Q35770478-8B48A4F9-446E-4BBF-80C3-73E6A435B52D

Q35770478-BB89C771-1D1F-45ED-98FB-C5AA9BD2E6C7

Q35770478-C425B441-E76B-4CD4-9587-A7071573DEC6

Q35770478-DFDB604C-B04D-43F1-AE82-30391AC54659

P2860

Q35770478-167F5298-C067-46A6-B8C4-E04328655144

Q35770478-1A0CD0E1-9DC8-4DFC-9D22-B9E0CACA3C1F

Q35770478-233AAA43-8568-4CC9-968D-0EC27DFE0610

Q35770478-24ECD14A-E550-478C-9537-181D98A4D446

Q35770478-2B4F4F08-405E-4A19-B3E9-B97B66F16060

Q35770478-481D6753-C137-4132-9FD0-CFDCB8E454AE

Q35770478-4BA60332-D845-440A-8BFB-93A7EB9A5AF9

Q35770478-5A49B0CB-9EBA-4486-833B-828E6F4B3C58

Q35770478-74014C1E-FB82-404C-A9A6-63DB8D53B3E9

Q35770478-75598D7A-D741-4126-B8BC-8DB5F5A1D3D8

P304

Q35770478-386B4BA0-8764-4BBA-B3FD-2EF1EF789EB9

P31

Q35770478-475886F9-8844-45CD-A6D5-F7AA883D3364

P356

Q35770478-2C531B56-1E42-47E4-802D-43F5D1809307

P407

Q35770478-C3DC33C0-B28A-4769-88E5-5E3D4E997C2F

P433

Q35770478-A2AB76BC-D8B4-4F00-9C20-C46AE32E8131

P478

Q35770478-4DD2001D-6E1B-4F0A-9FB8-BDB80FBD3DA7

P50

Q35770478-15B89BE3-4CFE-4AEA-8286-AA8A6FD2BD08

P577

Q35770478-DF672C2A-D007-4952-AF49-764F45033C13

P5875

Q35770478-755CBFB7-A8D3-4339-8FDC-823DB6832507

P698

Q35770478-93FB877C-700F-4BCF-A1F5-50C88F8524C0

P932

Q35770478-621EF0ED-FD7C-4DDA-9AD5-8ACAA2B14A50

P356

JCP.2005.031963

P1433

Journal of Clinical Pathology

P1476

Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression

@en

P2093

C Rubin

http://www.w3.org/2001/XMLSchema#string

M Kocherginsky

http://www.w3.org/2001/XMLSchema#string

M Tretiakova

http://www.w3.org/2001/XMLSchema#string

M Turkyilmaz

http://www.w3.org/2001/XMLSchema#string

T Grushko

http://www.w3.org/2001/XMLSchema#string

X J Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated

Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.

Controversies and advances in the management of Wilms' tumour.

Anthracyclines: selected new developments.

HER-2/neu and topoisomerase IIalpha in breast cancer.

Clinical and cellular pharmacology in relation to solid tumours of childhood.

Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?

Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why--and which.

Management of Wilms' tumour: current practice and future goals.

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

P304

1272-1277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JCP.2005.031963

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7222002

http://www.w3.org/2001/XMLSchema#string

P698

16556665

http://www.w3.org/2001/XMLSchema#string

P932

1860548

http://www.w3.org/2001/XMLSchema#string